170 related articles for article (PubMed ID: 33135102)
1. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma.
Sacdalan DB; Mendoza MJ; Vergara JP; Catedral LI; Ting FI; Leones LM; Berba CM; Sacdalan DL
Med Oncol; 2020 Nov; 37(11):106. PubMed ID: 33135102
[TBL] [Abstract][Full Text] [Related]
2. The drug treatment research of gastrointestinal cancer in China.
Ren C; Xu RH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e3-e6. PubMed ID: 32591201
[TBL] [Abstract][Full Text] [Related]
3. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
[TBL] [Abstract][Full Text] [Related]
4. Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives.
Zaaimi Y; Aparicio T; Laurent-Puig P; Taieb J; Zaanan A
Clin Res Hepatol Gastroenterol; 2016 Apr; 40(2):154-60. PubMed ID: 26547136
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
6. Target Therapy for Esophageal Adenocarcinoma.
Lam KO; Kwong DLW
Methods Mol Biol; 2018; 1756():51-65. PubMed ID: 29600359
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
[TBL] [Abstract][Full Text] [Related]
9. Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.
Hall PE; Spicer J; Popat S
Future Oncol; 2015; 11(15):2175-91. PubMed ID: 26039665
[TBL] [Abstract][Full Text] [Related]
10. An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids.
Takahashi N; Hoshi H; Higa A; Hiyama G; Tamura H; Ogawa M; Takagi K; Goda K; Okabe N; Muto S; Suzuki H; Shimomura K; Watanabe S; Takagi M
Cells; 2019 May; 8(5):. PubMed ID: 31137590
[TBL] [Abstract][Full Text] [Related]
11. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
12. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
13. Management of small bowel adenocarcinoma: making the most of the available evidence to inform routine practice.
Mazlom H; Teuwen LA; Peeters M
Curr Opin Oncol; 2021 Jul; 33(4):368-371. PubMed ID: 33882527
[TBL] [Abstract][Full Text] [Related]
14. Esophagogastric cancer: integration of targeted therapies into systemic chemotherapy.
Moehler M; Schwarz S; Wagner AD
Curr Cancer Drug Targets; 2011 Jul; 11(6):681-7. PubMed ID: 21651462
[TBL] [Abstract][Full Text] [Related]
15. Potential drug targets in small-bowel adenocarcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e436. PubMed ID: 28648558
[No Abstract] [Full Text] [Related]
16. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
De Grève J; Moran T; Graas MP; Galdermans D; Vuylsteke P; Canon JL; Schallier D; Decoster L; Teugels E; Massey D; Chand VK; Vansteenkiste J
Lung Cancer; 2015 Apr; 88(1):63-9. PubMed ID: 25682316
[TBL] [Abstract][Full Text] [Related]
17. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
19. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
20. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
